Table 2.
Features | Clinical–pathological features of 1023 melanoma patients | ||
---|---|---|---|
Male patients (n = 487) | Female patients (n = 536) | Pa | |
TMN stage (2009 AJCC melanoma staging system) | |||
Stage 0 | 72 (14.8%) | 109 (20.3%) | 0.025 |
Stage I | 243 (49.9%) | 306 (57.2%) | 0.025 |
Stage II | 103 (21.1%) | 80 (15%) | 0.012 |
Stage III | 23 (4.7%) | 17 (3.2%) | 0.264 |
Stage IV | 14 (2.9%) | 9 (1.7%) | 0.281 |
Unknown/not applicable | 32 (6.6%) | 15 (2.8%) | – |
Pathological TNM stage (pT) | |||
pTis | 72 (14.8%) | 107 (20.0%) | 0.036 |
pT1 | 188 (38.6%) | 241 (45.0%) | 0.046 |
pT2 | 78 (16.0%) | 88 (16.4%) | 0.929 |
pT3 | 64 (13.1%) | 49 (9.1%) | 0.053 |
pT4 | 50 (10.3%) | 32 (6.0%) | 0.016 |
Unknown/not applicable | 35 (7.2%) | 19 (3.6%) | – |
Histological ulceration | |||
Present | 80 (16.4%) | 52 (9.7%) | 0.002 |
Absent | 312 (64.1%) | 363 (67.7%) | 0.243 |
Unknown/not applicable | 95 (19.5%) | 121 (22.6%) | 0.261 |
Tumor-infiltrating lymphocytes | |||
Absent | 297 (61.0%) | 348 (64.9%) | 0.215 |
Non-brisk | 123 (25.3%) | 134 (25.0%) | 0.982 |
Brisk | 37 (7.6%) | 37 (6.9%) | 0.758 |
Unknown/not applicable | 30 (6.2%) | 17 (3.2%) | – |
Values in table are presented as the number (of patients) with the percentage in parenthesis
P ≤ 0.05 indicates a significant difference
aHomogeneity of proportions were obtained using the Pearson chi-squared test with Yates’ continuity correction, where necessary